Executive Summary for JPSHoldinf SC presentation, products and projects

1. JPSHolding
SC
Serving Life Sciences
Industries Since 1993
Proprietary & Confidential;

2. Core Business
 Portfolio Management
 Products evaluation
 Products development
 Licensing-In and Out
 Expert Reports
 Regulatory dossiers development and
submission: medicines, food supplements,
dietary foods for special medical purposes.
 Drug Delivery Technology
Proprietary & Confidential;

3. Licensing-in (for Clients)
 Paediatics
drugs, medical food, food
supplements
 BCAA
Proprietary & Confidential;

4. Licensing-out
 AS 21: skin ulcers treatment (medical
device)
 AS 22: mucitis treatment (medical device)
 Dualsetron®: Chemotherapy-Induced
Nausea and Vomiting treatment (Internal)
 Biridone®: Bipolar disorders (Internal)
 Thixans® technology: thixotropic
formulation
Proprietary & Confidential;

5. MEDICAL For of skin injuries
AS-21
Proprietary & Confidential;
CE Authorization 0459

6. FIRST SPECIFIC TREATMENT AGAINST:
 Bedsore (Superficial & Deep)
 Superficial & Deep Skin Injuries
 Pressure sore/Pressure ulcers
 Decubitus ulcers
 Diabetic skin ulcers
A NEW TRIPLE ACTION APPROACH
Proprietary & Confidential;

7. SALES
 New product: CE marking in August 2010
 2 Trial launch in Finland January 2010
 Sales Finland (Aktisor): 32 000
 Launched in Austria 2010 – 10 000 units
 Israel- February 2011
 Planned: Egypt, Middle East countries, India, Irak,
S. Africa, Australia,
Proprietary & Confidential;

8. AS 22 Specific treatment for
Chemotherapy Induced oral
mucositis (CIOM)
Proprietary & Confidential;

9. AS 22 OROCHEM®
 Mucitis following hemo and radiotherapy
 Colorless, odorless, sweet, viscous, 100
natural solution.
 Easy to apply, no side effects.
 Registered as a Class IIa medical device
due to its mechanical effects.
Proprietary & Confidential;

10. Dualsetron®
 Fixed-Dosecombination for
Chemotherapy-Induced Nausea And
Vomiting treatment.
Proprietary & Confidential;

11. Proprietary & Confidential;

12. Biridone®
 Bipolar-disorders
treament
 Patented formulation for once-day-
treatment
Proprietary & Confidential;

13. Development Status:
 CR formulation completed
 Analytical development completed
 Stability studies
 Pilot Pk study completed
 MBDD protocol completed
Proprietary & Confidential;

14. THIXANS®: THE THIXOTROPIC DEVICE
Pure or formulated active ingredient or
microparticulate dosage forms (pellets,
beadlets, spheroids etc..) manufactured
by usual pharmaceutical technologies
are embedded into a Thixotropic Cushion
® either extemporaneously or
regenerated by the microparticule itself.
Proprietary and Confidential: deNovelda
Farmaceutica

15. Thixotropic
Diffusion coating
Coating
Drug
Encapsulation
Technologies
Microspheres Thixotropic
Cushion®
Proprietary and Confidential: deNovelda
Farmaceutica